Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study

This study was originally designed as a phase I/II study, with a dose escalation of docetaxel in combination with epirubicin 50 mg m(−2) and 5-fluorouracil (5-FU) 200 mg m(−2) day(−1). However, as dose escalation was not possible, the study is reported as a phase II study of the combination to asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Humphreys, A C, Dent, J, Rodwell, S, Crawford, S M, Joffe, J K, Bradley, C, Dodwell, D, Perren, T J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409488/
https://www.ncbi.nlm.nih.gov/pubmed/15150554
http://dx.doi.org/10.1038/sj.bjc.6601840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409488/
https://www.ncbi.nlm.nih.gov/pubmed/15150554
http://dx.doi.org/10.1038/sj.bjc.6601840

Ejemplares similares